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Abstract
Background: A number of cross-sectional studies have highlighted 
a potential benefit of estrogen-containing contraception on serum 
25-hydroxyvitamin D (25(OH)D) levels. The purpose of the present 
prospective study was to determine whether oral vitamin D3 supple-
mentation significantly increases serum 25(OH)D more for women 
taking the estrogen-containing oral contraception than those not tak-
ing this medication.
Methods: Thirty-eight premenopausal adult females aged 18 - 45 
years old were recruited from a university campus; exclusion crite-
ria included those presently taking vitamin D supplementation, those 
who stopped or started taking oral contraception in last 6 months and 
those taking any other form of contraception. A prospective double-
blind placebo design was implemented; the dependent variable was 
serum 25(OH)D and the independent variables were using or not us-
ing oral estrogen-containing contraception, and vitamin D3 or placebo 
supplementation. Participants were tested 4 weeks apart, and blood 
samples were collected using a capillary blood spot sample method 
and analyzed by liquid chromatography-tandem mass spectrometry. 
An independent technician prepared the identical supplement bottles 
with either 100 placebo pills or 100 active vitamin D3 pills (1,000 IU 
per pill) and participants randomly selected a supplement bottle.
Results: Baseline measurements of 25(OH)D were non-significantly 
11% higher in those taking estrogen. ANOVA results revealed a sig-
nificant two-way interaction between supplementation group (treat-
ment vs. placebo) and treatment period (before vs. after) (P < 0.001), 
demonstrating a substantial rise in serum 25(OH)D for the treatment 
group compared with the placebo group. The results also identified 
a three-way interaction (P = 0.014) on serum 25(OH)D between the 
three independent variables, with the vitamin D oral contraception 
group having significantly greater serum 25(OH)D increases (from 
45.9 to 98.3 nmol/L) compared with those not taking oral contracep-
tion (44.2 - 69.6 nmol/L) (P = 0.019).
Conclusions: The estrogen-containing oral contraception increases 
serum 25(OH)D in premenopausal women with a magnified effect 
in those taking vitamin D supplementation. Future studies need to 
examine the relationship between estrogen, vitamin D supplementa-
tion, serum 25(OH)D, 1,25(OH)D, parathyroid hormone and other 
markers of bone metabolisms.
Keywords: Premenopausal; Vitamin D; Estrogen; Contraception; Fe-
male; Serum 25(OH)D; Intervention
Introduction
There is a high prevalence of vitamin D insufficiency and defi-
ciency across the world [1-3] and living near the equator, with 
its associated exposure to sunlight, does not necessary equate 
to adequate serum vitamin D status [4]. Deficiency is asso-
ciated with a range of medical disorders including metabolic 
bone disease [3, 5], type 2 diabetes [2], cancer and impaired 
immune function [6, 7]. It is also associated with muscle weak-
ness, which has been linked to the increased risk of falls in the 
elderly [5, 8] and to impaired athletic performance [9-11].
It is therefore important to be able to accurately measure 
vitamin D to identify those people with deficiency. Serum 
25-hydroxyvitamin D (25(OH)D) is the most stable circulating 
biomarker of vitamin D and is therefore measured in routine 
clinical practice. It exists in two major forms: 25(OH)D2 and 
25(OH)D3. The former is mainly plant-derived, whilst 25(OH)
D3 is obtained mainly from sunlight exposure and diet (dairy 
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products and fatty fish). Serum 25(OH)D3 has a higher biopo-
tency than 25(OH)D2 and therefore food fortification or sup-
plements are mainly given as vitamin D3 [12]. Serum 1,25-di-
hydroxyvitamin D is the active form of the vitamin but this is 
more difficult to measure.
Serum levels of 25(OH)D are influenced by a range of 
factors. Palaniswamy et al [13] reported that gender, season, 
diet, obesity and physical activity were all associated with low 
25(OH)D concentrations. A number of cross-sectional studies 
have reported that estrogen-containing hormonal contracep-
tion enhances serum 25(OH)D levels in women [10, 13, 14]. 
Harris and Dawson-Hughes [14] reported that women on con-
traception had 39% higher serum 25(OH)D levels compared 
with non-users. They also noted that five participants who 
ceased taking oral contraception during the following year had 
decreases in their 25(OH)D levels. The underlying mechanism 
for this is unclear at present, although there are at least two 
possible mechanisms: estrogen increases vitamin D 25-hy-
droxylase activity in the liver [15], and it causes an increased 
circulating concentration of vitamin D binding protein [16]. 
Both these mechanisms could increase 25(OH)D levels but it 
is still unclear whether this has a physiological effect on bone 
metabolism.
The previous studies have been observational in nature. 
The purpose of the present prospective study was to deter-
mine whether oral vitamin D3 supplementation significantly 
increases serum 25(OH)D more for women taking the estro-
gen-containing oral contraception than those not taking this 
medication.
Materials and Methods
Participants
Premenopausal adult females aged between 18 and 45 years 
old were recruited from a university campus (latitude 52.58 
°N) during the month of March. Participant exclusion criteria 
included those presently taking vitamin D supplementation, 
those who stopped or started taking oral contraception in last 6 
months and those taking any other form of contraception, e.g. 
implant. Inclusion criteria for participants taking oral contra-
ception required a minimum of 6 months using estrogen-con-
taining contraception. Required sample size was calculated, 
based upon data provided by Harris and Dawson-Hughes [14], 
as six participants per group (oral contraception + vit D sup-
plementation; oral contraception + placebo; no contraception 
+ vit D supplementation; no contraception + placebo) based 
upon magnitude of effect at 90% confidence intervals [17]. To 
account for blinded nature of the study and potential dropout, it 
was decided to recruit 60 participants. Fifty-eight female par-
ticipants volunteered for the study and 20 dropped out (34%) 
during its course (Table 1).
Experimental design
A prospective double-blind placebo design was implemented. 
The dependent variable was serum 25(OH)D and the independ-
ent variables were using or not using oral estrogen-containing 
contraception, and vitamin D3 or placebo supplementation.
An independent technician prepared the identical supple-
ment bottles with either 100 placebo pills or 100 active vitamin 
D3 pills (1,000 IU per pill) that had uniform appearance. Us-
ing an online random number generator (www.sealedenvelope.
com), all bottles were allocated a number using a 1:1 alloca-
tion. Participants, outcome assessors, and data analysts were 
kept blinded to the allocation, and the independent researcher 
unblinded the trial post data analysis. The entire protocol was 
approved by a university Ethics Committee.
Protocol
Participants were tested 4 weeks apart. Recorded sunlight 
during this period was 124.8 h. Each participant completed 
informed consent before anthropometric measurements and 
blood collection. Standing height was measured to the nearest 
0.1 cm using a Seca stadiometer (Hamburg, Germany), with 
the participants in bare feet and their heads in Frankfort hori-
zontal plane. Total body mass was measured to the nearest 0.5 
kg with a Seca beam balance 710 (Hamburg, Germany), and 
participants wore minimal clothing. Using a capillary blood 
spot sample method, the tester used a single use lancet on the 
participant’s selected finger and the first show of blood was 
wiped away. Four blood spots were collected on the blood col-
lection card (City Assays, Birmingham, UK) making sure the 
spots were of sufficient size and had soaked through the paper. 
The card was then sealed before being sent to an independ-
ent laboratory for analysis (City Assays, Pathology Depart-
ment Sandwell and West Birmingham Hospital NHS Trust, 
UK). Each participant was asked to select a number from a 
number grid 1-60. The relevant supplement sample was then 
issued to the participant with the instructions to complete the 
Table 1.  Participants’ Descriptive Data
Group
Age (years) Height (cm) Weight (kg) BMI
Contraception Supplementation
Yes Vit D (n = 10) 24 ± 5.99 165.56 ± 9.74 67.0 ± 9.23 20.18 ± 1.92
Placebo (n = 9) 30 ± 11.62 161.50 ± 9.03 64.3 ± 5.63 19.88 ± 1.39
No Vit D (n = 10) 22 ± 4.55 169.22 ± 6.41 70.6 ± 12.33 20.77 ± 2.97
Placebo (n = 9) 27 ± 10.71 166.33 ± 6.32 68.8 ± 9.28 20.66 ± 2.61
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supplementation within 3 days. Blood data collection occurred 
again 4 weeks later. After the study, the lead author contacted 
all participants to feedback their individual results and provide 
participants who had been on the placebo trial with vitamin D3 
supplementation.
Blood analysis
A liquid chromatography-tandem mass spectrometry (LC-MS/
MS) method was applied to dried blood spot samples, utiliz-
ing blood spot calibrators. The method is standardized against 
conventional 25-hydroxyvitamin D3 and D2 LC-MS/MS ser-
vice for serum. Blood spot results showed good comparabil-
ity to serum/plasma results (r2 = 0.98; intra-assay variation < 
10%; inter-assay variation < 11%). The City Assays laboratory 
participates in the DEQAS external quality assurance scheme.
Data analysis
A three-way repeated-measures ANOVA was used to detect 
changes in serum 25(OH)D due to the independent variables, 
either using or not using oral contraception, and vitamin D3 or 
placebo supplementation, before and after being given the vi-
tamin D3 or placebo supplementation. The repeated-measures 
factors were: oral contraception (yes or no) and vitamin D3 
supplementation (vitamin D3 or placebo) as the two between 
subject factors, and the treatment period (before or after being 
given the supplementation) as the third within-subject factor.
Results
There was no difference in the age and anthropometric meas-
urements between the groups (Table 1). The baseline measure-
ments of 25(OH)D were 11% higher in those taking estrogen 
(48.1 ± 27.33 vs. 43.5 ± 20.64 nmol/L), but this did not react 
statistical significance.
The ANOVA results revealed a significant two-way inter-
action between supplementation group (treatment vs. placebo) 
and treatment period (before vs. after) (P < 0.001), demon-
strating a substantial rise in serum 25(OH)D for the treatment 
group compared with the placebo group, following the period 
of supplementation (Table 2). However, the ANOVA results 
also identified a three-way interaction (P = 0.014) on serum 
25(OH)D between the three independent variables (Fig. 1).
Clearly, the benefits of being given vitamin D can be seen 
in both groups (Fig. 1, as described in the two-way interaction 
above), but the benefit of being given vitamin D is significantly 
greater in those taking oral contraception compared with those 
not taking oral contraception (P = 0.019). The take-up of serum 
25(OH)D by those taking oral contraception is over 52 nmol/L 
(from 45.9 to 98.3 nmol/L) compared with only 25 nmol/L 
(44.2 - 69.6 nmol/L) for those not on oral contraception.
Discussion
The present prospective study showed that both groups on vi-
tamin D3 supplementation increased serum 25(OH)D levels 
but the group that was also on estrogen-containing oral con-
traception reported a further 100% increase compared to those 
who were not taking this medication. This study supports the 
observations of previous cross-sectional and longitudinal ob-
servation studies that oral contraception has a positive effect 
on serum 25(OH)D levels [10, 14]. Our study also showed 
those taking the estrogen-containing oral contraceptive had 
11% higher baseline 25(OH)D but this did not reach statistical 
significance. Studies by Harris and Dawson-Hughes [14] and 
Harmon et al [18] have both shown significant larger increases 
in 25(OH)D for those on the oral contraceptive of 20-39%. It is 
difficult to provide an explanation for these differences, but all 
three studies demonstrate that 25(OH)D serum levels increase 
in response to the estrogen-containing oral contraceptive. Our 
study also shows that this effect is enhanced when taking high-
dose vitamin D supplementation.
Two mechanisms have been proposed for the increase in 
25(OH)D. Nelson et al [15] suggested estrogen-containing 
oral contraception increased vitamin D 25-hydroxylase activ-
ity in the liver, whilst Moller et al [16] proposed the increase 
was due to an increase in circulating concentration of vitamin 
D binding protein (VDBP). However, it is currently unclear 
whether this biochemical response of 25(OH)D occurs in iso-
lation or whether it is associated with an increase in vitamin D 
activity on bone metabolism. It is possible that, if the increase 
in 25(OH)D is due to an increase in the circulating VDBP with 
an increase in bound vitamin D, this may not be accompanied 
by an increase in bio-activity. This may be of some concern as 
we use 25(OH)D as a clinical marker of vitamin D status. An 
increase in this marker due to estrogen supplementation may 
mask a potential deficiency in vitamin D bio-activity.
Table 2.  Descriptive Pre and Post Serum 25(OH)D Data
Group Serum 25(OH)D
Contraception Supplementation Pre (nmol/L) Post (nmol/L)
Yes Vit D (n = 10) 52.3 ± 33.65 98.3 ± 37.02*Ŧ
Placebo (n = 9) 43.5 ± 19.00 45.9 ± 2.06
No Vit D (n = 10) 47.5 ± 24.85 69.6 ± 24.21*
Placebo (n = 9) 39.0 ± 14.86 44.2 ± 15.79
*Significant change pre and post (P < 0.001). ŦSignificant greater increase compared to other groups (P = 0.019).
FO
R  
PR
O
OF
RE
AD
I N
G
FO
R  
PR
O
OF
RE
AD
I N
G
Articles © The authors   |   Journal compilation © J Endocrinol Metab and Elmer Press Inc™   |   www.jofem.org4
Hormonal Contraception on Vitamin D J Endocrinol Metab. 2017;000(000):000-000
Future prospective studies should therefore assess wheth-
er the increase in 25(OH)D is associated with parallel changes 
in serum 1,25(OH)D, parathyroid hormone (PTH) and other 
markers of bone metabolism. Wolman et al [10] noted a sig-
nificant decrease in PTH for those on oral contraception that 
was association with a significant increase in serum 25(OH)D 
above the levels reported for those not taking oral contracep-
tion. The study was limited by low numbers of participants on 
contraception [5] and therefore the results cannot be general-
ized further.
The observed vitamin D response to the estrogen-con-
taining oral contraceptive raises the question as to whether 
there is a vitamin D response to other situations where there 
is a change in estrogen. In studies on postmenopausal women 
taking hormone replacement therapy (HRT), one reported a 
significant increase in vitamin D binding protein [19], whilst 
another showed no increased benefit on bone mineral content 
[20]. Heikkinen et al [21] reported a 38.2% increase in serum 
25(OH)D for participants taking HRT and vitamin D3, but this 
was only a slightly greater increase than the vitamin D3 only 
group (33.5%). It is also possible that vitamin D levels may 
change in response to those going through the menarche and 
the menopause. Further studies are needed to address these 
questions.
In conclusion, the estrogen-containing oral contraception 
increases serum 25(OH)D in premenopausal women with a 
magnified effect in those taking vitamin D supplementation. 
Future studies need to examine the relationship between estro-
gen, vitamin D supplementation, serum 25(OH)D, 1,25(OH)
D, PTH and other markers of bone metabolism.
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Figure 1. Changes in serum 25(OH)D. *Significant change pre and post (P < 0.001). ŦSignificant greater increase compared to 
other groups (P = 0.019).
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